The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells

@article{Sabit2016TheRO,
  title={The Role of Sodium Phenylbutyrate in Modifying the Methylome of Breast Cancer Cells},
  author={Hussein Sabit and A. T. El-Garhy and Mokhtar M. El-Zawahry},
  journal={International journal of scientific and engineering research},
  year={2016},
  volume={7},
  pages={677-683}
}
Sodium phenylbutyrate is one of the histone deacetylase inhibitors that play a role as an anti-cancer agent. One of the diseases that could be challenged with sodium phenylbutyrate is breast cancer, which is the most common cancer and the leading cause of cancer death in females worldwide. In the present study, the role of sodium phenylbutyrate was investigated along with different chemotherapeutic drugs in controlling breast cancer cells (MCF-7). Two concentrations were used in the current… 
1 Citations

Figures and Tables from this paper

Understanding Breast cancer: from conventional therapies to repurposed drugs.

References

SHOWING 1-10 OF 52 REFERENCES

Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.

The rationales and clinical progress of several combinations with HDAC inhibitors are presented, including DNA-damaging chemotherapeutic agents, radiotherapy, hormonal therapies, DNA methyltransferase inhibitors and various small-molecule inhibitors.

Clinical and Experimental Applications of Sodium Phenylbutyrate

Sodium phenylbutyrate is a histone deacetylase inhibitor that has been approved for treatement of urea cycle disorders and is under investigation in cancer, hemoglobinopathy, motor neuron diseases, and cystic fibrosis clinical trials.

Lidocaine Sensitizes the Cytotoxicity of Cisplatin in Breast Cancer Cells via Up-Regulation of RARβ2 and RASSF1A Demethylation

The present study confirms the dem methylation effect of lidocaine in breast cancer cells, and found that the demethylation of RARβ2 and RASSF1A sensitized the cytotoxicity of cisplatin in breastcancer cells.

Histone Deacetylase Inhibitors in Clinical Studies as Templates for New Anticancer Agents

Four major structural classes of HDAC inhibitors that are in clinical trials and different computer modeling tools available for their structural modifications are summarized as a guide to discover additional HDAC inhibitor-based therapies with greater therapeutic utility.

Trastuzumab enhances the anti-tumor effects of the histone deacetylase inhibitor sodium butyrate on a HER2-overexpressing breast cancer cell line.

In conclusion, trastuzumab significantly improved the antitumor effect of NaB on HER2-overexpressing breast cancer cell line in vitro.

Chemosensitization of rhabdomyosarcoma cells by the histone deacetylase inhibitor SAHA.

Sodium Phenylbutyrate Controls Neuroinflammatory and Antioxidant Activities and Protects Dopaminergic Neurons in Mouse Models of Parkinson’s Disease

It is demonstrated that sodium phenylbutyrate (NaPB), an FDA-approved therapy for reducing plasma ammonia and glutamine in urea cycle disorders, can suppress both proinflammatory molecules and reactive oxygen species (ROS) in activated glial cells and suggested that NaPB may be of therapeutic benefit for neurodegenerative disorders.
...